Sona Deshmukh, MBBS, MPH

Pune, India
Role: 
Staff
Study Coordinator
Sona Deshmukh, MBBS, MPH

Dr. Deshmukh is Study Coordinator for the Tuberculosis-Diabetes study at the Byramjee Jeejeebhoy Government Medical College-JHU Clinical Research Site, funded by the NIH/National Institute of Allergy and Infectious Diseases (NIAID). Her research interests include the epidemiology of noncommunicable diseases and policy reforms for the same.

The BJGMC Clinical Research Site is a member of a the Baltimore-Washington-India Clinical Trials Unit, a collaborative research partnership among BJGMC, Johns Hopkins School of Medicine, and Whitman Walker Health in Washington, DC, to conduct clinical research for the world’s largest HIV therapeutic trial networks: the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric and Adolescent AIDS Clinical Trial Network (IMPAACT).

Dr. Deshmukh has more than five years of experience in public health, programme management, policy design, and community-based research studies for noncommunicable diseases. She has published two research publications. Following a short tenure as Medical Officer in a government hospital, she worked under the dynamic leadership of Dr. Abhay Bang for two years in their esteemed research organization SEARCH, in Gadchiroli, India. Here she designed, implemented, and managed various community-based research projects conducted in 86 villages in Gadchiroli.

Further she took the opportunity to work in the state health department for three years as District Programme Officer to implement and monitor the National Programme for Prevention and Control of Non Communicable Diseases in Chandrapur, Maharashtra. Following her field experience, she briefly served for six months as a senior consultant for public health to government of Maharashtra.

Dr. Deshmukh received a MBBS in medicine from Maharashtra University of Health Sciences in Nashik, India, and a Master of Public Health degree from Tata Institute of Social Sciences (TISS) in Mumbai, India.

Increasing Market and Public Health Outcomes Through Scaling Up Affordable Access Models of Short Course Preventive Therapy for TB (IMPAACT4TB)

Post Date: 
2019-12-17
   |   
Countries: 
   |   
Clinical Sites: 
Primary Objective: This study is being conducted in Brazil, Cambodia, China, Ethiopia, Ghana, Haiti, India, Indonesia, Kenya, Malawi, Mozambique, South Africa, Tanzania, and Zimbabwe. The overall goal is to reduce TB incidence among (1) people living with HIV who are on antiretroviral therapy, and...

A Phase 2a, Double-Blind, Placebo-Controlled, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of ID93 + GLA-SE Vaccine Administered to HIV-Negative Patients at 3 Time Points During Multidrug Therapy for Drug Susceptible Pulmonary TB

Post Date: 
2019-10-28
   |   
Clinical Sites: 
This study was terminated in April 2020. Vidya Mave was PI of this HIV vaccine trial. BACKGOUND: Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis (Mtb). TB is one of the leading causes of morbidity and mortality around the world with an estimated 10...

Impact of Diabetes on TB Treatment Outcomes

Post Date: 
2013-02-01
   |   
Countries: 
   |   
Clinical Sites: 
CCGHE, the JHU Center for TB Research and BJGMC have been awarded a $2.5 million dollar NIH grant (2013-2018) to conduct a study to evaluate treatment outcomes among Indian patients with both diabetes mellitus and active TB. This study is assessing the prevalence of impaired glucose or frank...

BWI CTU: Baltimore-Washington-India Clinical Trials Unit

Post Date: 
2007-02-02
   |   
Countries: 
   |   
Clinical Sites: 
Comprising clinical trial sites at Johns Hopkins Medicine in Baltimore, Whitman Walker Health in Washington, DC, and the BJGMC-CCGHE collaboration in Pune, India, the Baltimore-Washington-India Clinical Trials Unit (BWI-CTU) is one of only 25 international HIV/TB clinical trial sites funded by the...

Assessment of the Xpert assay among new pulmonary tuberculosis suspects with and without diabetes mellitus

Post Date: 
2020-01-01
   |   
Clinical Sites: 
Publication: 
International Journal of Tuberculosis and Lung Disease
IJTLD: Deshmukh and colleagues: High sensitivity and specificity of Xpert underscores need for rapid scale up for early detection of TB in settings with a high dual burden of TB and DM

Lipid mediators of inflammation and resolution in individuals with tuberculosis and tuberculosis-diabetes

Post Date: 
2019-11-11
Publication: 
Prostaglandins and Other Lipid Mediators
Individuals with concurrent tuberculosis (TB) and Type 2 diabetes (DM) have a higher risk of adverse outcomes. To better understand potential immunological differences, we utilized a comprehensive panel to characterize pro-inflammatory and pro-resolving (i.e., mediators involved in the...

The effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment

Post Date: 
2018-08-20
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
Antimicrobial Agents and Chemotherapy
DM and higher HbA1c increased the risk of not achieving therapeutic targets for pyrazinamide, but higher pyrazinamide concentrations were asociated with worse microbiologic and clinical outcomes

Trends in HbA1c levels and implications for diabetes screening in tuberculosis cases undergoing treatment in India

Post Date: 
2018-07-01
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
International Journal of Tuberculosis and Lung Disease
SETTING: The optimal timing of screening for diabetes mellitus (DM) among tuberculosis (TB) cases is unclear due to the possibility of stress hyperglycemia. DESIGN: We evaluated adult (18 years) pulmonary TB cases at treatment initiation as well as at 3 months,...

Prevalence of dysglycemia and clinical presentation of pulmonary tuberculosis in Western India

Post Date: 
2017-12-01
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
International Journal of Tuberculosis and Lung Disease
Objectives: To estimate the prevalence and risk factors of pre-diabetes mellitus (DM) and DM, and its associations with the clinical presentation of tuberculosis (TB). Design: Screening for DM was conducted among adults (age  18 years) with confirmed TB between December 2013 and...

Trends in Glycated Hemoglobin Levels and Implications for Diabetes Screening among Pulmonary Tuberculosis Cases Undergoing Treatment in India

Post Date: 
2017-09-13
   |   
Countries: 
   |   
Clinical Sites: 
Gupte AN , Mave V, Meshram S, Lokhande R, Kadam D, Dharmshale S, Bharadwaj R, Kagal A, Pradhan N, Deshmukh S, Atre S, Sahasrabudhe T, Barthwal M, Meshram S, Kakrani A, Kulkarni V, Raskar S, Suryavanshi S, Shivakoti R, Chon S, Selvin E, Gupte N, Gupta A, Golub JE. Trends in Glycated Hemoglobin...

Xpert® MTB/RIF Assay for Pulmonary Tuberculosis Diagnosis in Patients with Diabetes Mellitus

Post Date: 
2016-10-27
   |   
Clinical Sites: 
Mave V , Gupte N, Meshram S, Kagal A, Gupta A, Bharadwaj R, Pradhan N, Deshmukh S, Atre S, Golub J. Xpert® MTB/RIF Assay for Pulmonary Tuberculosis Diagnosis in Patients with Diabetes Mellitus. 47th Union World Conference on Lung Health. International Union for Tuberculosis and Lung Disease...